No Data
No Data
Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate
Pyxis Oncology Will Present New Preclinical Data Supporting Development Of First-In-Concept Antibody-Drug Conjugate Targeting EDB+FN In Tumor Microenvironment At AACR 2025
Express News | Pyxis Oncology To Present Preclinical Data On Potential Of PYX-201 At AACR 2025, Apr. 28
Pyxis Oncology Highlights Strategic Focus on Lead Candidate
Jefferies Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $6
Citi Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5